Graphite Bio Cuts Sickle Cell Therapy, Half of Staff

A once highly touted gene therapy for sickle cell disease (SCD) has come to an end, at least internally, as Graphite Bio announced Thursday it is discontinuing the development of nulabeglogene autogedtemcel (nula-cel), its lead asset.